产品名称
羟基脲, European Pharmacopoeia (EP) Reference Standard
InChI
1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
SMILES string
NC(=O)NO
InChI key
VSNHCAURESNICA-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
hydroxycarbamide
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... RRM1(6240), RRM2(6241), RRM2B(50484)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
抗肿瘤剂。通过形成自由基硝基氧灭活核糖核苷还原酶，自由基硝基氧可结合到酶活性位点的酪氨酰自由基。这可阻断脱氧核苷酸的合成，从而抑制 DNA 合成，并且诱导细胞周期同步化或 S-期细胞死亡。
Application
Hydroxycarbamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
hcodes
pcodes
Hazard Classifications
Muta. 1B - Repr. 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Alessandro M Vannucchi et al.
The New England journal of medicine, 372(5), 426-435 (2015-01-30)
Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of
Patrick T McGann et al.
Current opinion in hematology, 18(3), 158-165 (2011-03-05)
Sickle cell anemia (SCA) is a well characterized severe hematological disorder with substantial morbidity and early mortality. Hydroxyurea is a potent inducer of fetal hemoglobin, and evidence over the past 25 years has documented its laboratory and clinical efficacy for
A Tefferi et al.
Leukemia, 28(12), 2300-2303 (2014-05-06)
The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining
John J Strouse et al.
Pediatrics, 122(6), 1332-1342 (2008-12-03)
Hydroxyurea is the only approved medication for the treatment of sickle cell disease in adults; there are no approved drugs for children. Our goal was to synthesize the published literature on the efficacy, effectiveness, and toxicity of hydroxyurea in children
Pilvi Riihilä et al.
The Journal of investigative dermatology, 135(2), 579-588 (2014-09-04)
The incidence of cutaneous squamous cell carcinoma (cSCC) is rising worldwide. We have examined the role of complement components in the progression of cSCC. Analysis of cSCC cell lines (n=8) and normal human epidermal keratinocytes (n=11) with whole transcriptome profiling
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持